India, Oct. 8 -- Shares of argenx SE (ARGX) are tumbling 15% after the company said it will discontinue its Phase 3 UNITY study of efgartigimod SC in Sjogren's disease after an interim analysis found the trial was futile.
The stock is currently trading at $790.89, down $137.55 or 14.81%, on the Nasdaq. It opened at $831.71 after closing the previous session at $928.44. The stock has traded between $661.85 and $1,072.75 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....